Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
pharmaphorum2d
Novo Nordisk, Lilly highlight oral obesity drugs at ADA
New data from Novo Nordisk’s phase 3 trial of an oral ... in a way that best suits them,” said Professor Filip Knop of Gentofte Hospital, University of Copenhagen, who presented the results ...
NVO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Novo Nordisk A/S to Contact the Firm Today!
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors ...
Hosted on MSN13d
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line ...
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs. Net profit for the fourth ...